EP 3818044 A1 20210512 - COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY
Title (en)
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY
Title (de)
VERBINDUNGEN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ERKRANKUNGEN IN ZUSAMMENHANG MIT STING-AKTIVITÄT
Title (fr)
COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE STING
Publication
Application
Priority
- US 201862693878 P 20180703
- US 201962861078 P 20190613
- US 2019040418 W 20190702
Abstract (en)
[origin: WO2020010155A1] This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
IPC 8 full level
C07D 207/34 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/4025 (2006.01); A61K 31/4155 (2006.01); A61K 31/4164 (2006.01); A61K 31/4178 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); C07D 231/40 (2006.01); C07D 233/88 (2006.01); C07D 261/14 (2006.01); C07D 263/48 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 405/12 (2006.01); C07D 409/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01)
CPC (source: EP US)
A61K 9/0019 (2013.01 - US); A61K 31/282 (2013.01 - US); A61K 31/337 (2013.01 - US); A61K 31/40 (2013.01 - US); A61K 31/415 (2013.01 - US); A61K 31/4155 (2013.01 - US); A61K 31/4164 (2013.01 - US); A61K 31/427 (2013.01 - US); A61K 31/437 (2013.01 - US); A61K 31/4439 (2013.01 - US); A61K 31/4725 (2013.01 - US); A61K 31/675 (2013.01 - US); A61K 31/704 (2013.01 - US); A61K 31/7048 (2013.01 - US); A61K 33/243 (2019.01 - US); A61K 38/09 (2013.01 - US); A61K 38/12 (2013.01 - US); A61K 38/14 (2013.01 - US); A61K 39/3955 (2013.01 - US); A61K 45/06 (2013.01 - US); A61P 29/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); C07D 207/34 (2013.01 - EP US); C07D 231/40 (2013.01 - EP US); C07D 233/88 (2013.01 - EP US); C07D 261/14 (2013.01 - EP); C07D 263/48 (2013.01 - EP); C07D 401/04 (2013.01 - US); C07D 401/12 (2013.01 - EP US); C07D 401/14 (2013.01 - EP); C07D 403/04 (2013.01 - EP); C07D 405/12 (2013.01 - EP); C07D 409/04 (2013.01 - EP US); C07D 413/04 (2013.01 - EP); C07D 417/04 (2013.01 - EP US); C07D 471/04 (2013.01 - US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020010155 A1 20200109; CN 112823151 A 20210518; EP 3818044 A1 20210512; JP 2021529834 A 20211104; JP 7482122 B2 20240513; MA 53096 A 20210512; US 2021236466 A1 20210805
DOCDB simple family (application)
US 2019040418 W 20190702; CN 201980057351 A 20190702; EP 19745422 A 20190702; JP 2021522935 A 20190702; MA 53096 A 20190702; US 201917257225 A 20190702